Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations

NCT06980805 is registered in ClinicalTrials.gov with Immunovant Sciences GmbH as lead sponsor.

NCT NCT06980805
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06980805 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants With Active Subacute Cutaneous Lupus Erythematosus (SCLE) and/or Chronic Cutaneous Lupus Erythematosus (CCLE) With or Without Systemic Manifestations
Lead sponsor
Immunovant Sciences GmbH
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 19, 2025
Completion date
April 30, 2027
Enrollment
56 (estimated)
Sites
86

Conditions

As the registry lists them; a condition with its own page is linked.

chronic cutaneous lupus erythematosus, subacute cutaneous lupus erythematosus